Merck highlights oncology pipeline and cancer vaccine trial at ESMO 2026
read at Endpoints ↗Neutral
Merck attended the European Society for Medical Oncology (ESMO) meeting in Madrid, using the conference to present updates on its oncology portfolio.
Media coverage largely centered on the company's collaborative cancer vaccine trial with Moderna, which drew significant attention at the event.
Beyond the vaccine, Merck used the platform to discuss a range of pipeline candidates across various cancer indications, underscoring its broader development strategy.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?”
read at Endpoints ↗83 words · retrieved 33m ago
comments(0)
5-min edit window · permanent after that